Skip to main content

Advertisement

SpringerLink
Log in

Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy

  • ORIGINAL ARTICLE
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Although imatinib has shown high activity in the majority of patients with advanced gastrointestinal stromal tumors (GIST), it has become clear that secondary resistance appears during chronic therapy. The aim of this study was to retrospectively analyze the safety and prognostic effects of surgical interventions for focal progression during imatinib treatment.

Methods

Between January 2002 and May 2005, 16 patients who had focal lesions of secondary-resistant GIST to imatinib treatment (male/female, 12 : 4; median age, 62 years) underwent surgical interventions such as resection, radiofrequency ablation, and their combination.

Results

Postoperative complications, including liver abscess, bile leak, wound infection, and ileus were mostly mild, and the patients recovered with conservative therapy. There was no hospital death. The median time to progression (TTP) of all patients was 5.5 months, and only one patient died of the disease; the others are alive after a median follow up of 12.4 months. Patients with complete resections of resistant lesions (n = 7) showed significantly better median TTP than those with incomplete resections (n = 9; P = 0.014). The impact of curability on focal lesions with secondary resistance was mainly significant in patients with tumors of stomach origin (P = 0.013), and a smaller number (P = 0.014) and smaller size (P = 0.018) of resistant lesions. Overall survival was 100% at 1 year and 75% at 2 years.

Conclusion

Our study indicates that surgical interventions in patients with GIST resistant to imatinib therapy are efficacious when complete resections are performed, when the lesions are of gastric origin, when the number of lesions is lower, and when the lesions are a smaller size.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. T Nishida S Hirota (2000) ArticleTitleBiological and clinical review of stromal tumors in the gastrointestinal tract Histol Histopathol 15 1293–1301 Occurrence Handle11005253 Occurrence Handle1:STN:280:DC%2BD3cvltValuw%3D%3D

    PubMed  CAS  Google Scholar 

  2. RP DeMatteo MC Heinrich WM El-Rifai et al. (2002) ArticleTitleClinical management of gastrointestinal stromal tumors: before and after STI-571 Hum Pathol 33 466–477 Occurrence Handle12094371 Occurrence Handle10.1053/hupa.2002.124122 Occurrence Handle1:CAS:528:DC%2BD38XlslCls7o%3D

    Article  PubMed  CAS  Google Scholar 

  3. RP DeMatteo JJ Lewis D Leung et al. (2002) ArticleTitleTwo hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival Ann Surg 231 51–58 Occurrence Handle10.1097/00000658-200001000-00008

    Article  Google Scholar 

  4. PJ Roberts B Eisenberg (2001) ArticleTitleClinical presentation of gastrointestinal stromal tumors and treatment of operative disease Eur J Cancer 38 S37–38 Occurrence Handle10.1016/S0959-8049(02)80601-3

    Article  Google Scholar 

  5. AT Van Oosterom I Judson J Verweij et al. (2001) ArticleTitleSafety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study Lancet 358 1421–1423 Occurrence Handle11705489 Occurrence Handle10.1016/S0140-6736(01)06535-7 Occurrence Handle1:CAS:528:DC%2BD3MXot1Ojtb0%3D

    Article  PubMed  CAS  Google Scholar 

  6. H Joensuu PJ Roberts M Sarlomo-Rikala et al. (2001) ArticleTitleEffect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 1052–1056 Occurrence Handle11287975 Occurrence Handle10.1056/NEJM200104053441404 Occurrence Handle1:STN:280:DC%2BD3M3gvVekuw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  7. GD Demetri M von Mehren CD Blanke et al. (2002) ArticleTitleEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472–480 Occurrence Handle12181401 Occurrence Handle10.1056/NEJMoa020461 Occurrence Handle1:CAS:528:DC%2BD38XmtV2nt7s%3D

    Article  PubMed  CAS  Google Scholar 

  8. J Verweji PG Casali J Zalcberg et al. (2004) ArticleTitleProgression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial Lancet 364 1127–1134 Occurrence Handle10.1016/S0140-6736(04)17098-0

    Article  Google Scholar 

  9. C Rankin M von Mehren C Blanke et al. (2004) ArticleTitleContinued prolongation of survival by imatinib with metastatic GIST. Update of results from North American Intergroup phase III study S0033 (abstract) Proc Am Soc Clin Oncol 23 815

    Google Scholar 

  10. GD Demetri R Benjamin CD Blanke et al. (2004) ArticleTitleOptimal management of patients with gastrointestinal stromal tumor (GIST) – expansion and update of NCCN Clinical Practice Guidelines J Natl Compr Canc Netw 2 S1–S26

    Google Scholar 

  11. JY Blay S Bonvalot P Casali et al. (2005) ArticleTitleConsensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST consensus conference of 20–21 March 2004, under the auspices of ESMO Ann Oncol 16 566–578 Occurrence Handle15781488 Occurrence Handle10.1093/annonc/mdi127

    Article  PubMed  Google Scholar 

  12. JR Zalcberg J Verweji PG Casali et al. (2004) ArticleTitleOutcome of patients with advanced gastro-intestinal stromal tumours (GIST) crossing over to a daily imatinib dose of 800 mg (HD) after progression on 400 mg (LD) – an international, intergroup study of EORTC, ISG and AGITG (abstract) Proc Am Soc Clin Oncol 23 815

    Google Scholar 

  13. GD Demetri AT van Oosterom M Blackstein et al. (2005) ArticleTitlePhase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST (abstract) Proc Am Soc Clin Oncol 23 308

    Google Scholar 

  14. RG Maki JA Fletcher MC Heinrich et al. (2005) ArticleTitleSU11248 in patients with imatinib-resistant GIST: results from a continuation trial (abstract) Proc Am Soc Clin Oncol 23 818

    Google Scholar 

  15. S Bauer JT Hartmann M de Wit et al. (2005) ArticleTitleResection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib Int J Cancer 117 316–325 Occurrence Handle15900603 Occurrence Handle10.1002/ijc.21164 Occurrence Handle1:CAS:528:DC%2BD2MXhtVygsrfK

    Article  PubMed  CAS  Google Scholar 

  16. A Gronchi M Fiore R Bertulli et al. (2005) ArticleTitleSurgery of residual disease following imatinib mesylate in advanced gastrointestinal stromal tumors (GIST) (abstract) Proc Am Soc Clin Oncol 23 825

    Google Scholar 

  17. P Rutkowski Z Nowecki P Nyckowski et al. (2005) ArticleTitleSurgical treatment of patients (pts) with gastrointestinal stromal tumors (GIST) after imatinib mesylate (IM) therapy (abstract) Proc Am Soc Clin Oncol 23 825

    Google Scholar 

  18. P Hohenberger C Langer S Pistorius et al. (2006) ArticleTitleIndication and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST) (abstract) Proc Am Soc Clin Oncol 24 520s

    Google Scholar 

  19. LL Chen M Sabripour RHI Andtbacka et al. (2005) ArticleTitleImatinib resistance in gastrointestinal stromal tumors Curr Oncol Rep 7 293–299 Occurrence Handle15946589 Occurrence Handle10.1007/s11912-005-0053-6 Occurrence Handle1:CAS:528:DC%2BD28XktVarsw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  20. NG Eng-hen RE Pollock MF Munsell et al. (1992) ArticleTitlePrognostic factors influencing survival in gastrointestinal leiomyosarcomas Ann Surg 215 68–77

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

    Junichi Hasegawa, Akiko Nishitani, Tsuyoshi Takahashi & Toshirou Nishida

  2. Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

    Tatsuo Kanda, Isao Kurosaki & Katsuyoshi Hatakeyama

  3. Department of Surgical Pathology, Hyogo College of Medicine, Hyogo, Japan

    Seiichi Hirota & Akiko Nishitani

  4. Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata, Japan

    Masafumi Fukuda

  5. Department of Internal Medicine, Osaka University Graduate School of Medicine, Osaka, Japan

    Shusaku Tsutsui

Authors
  1. Junichi Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tatsuo Kanda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seiichi Hirota
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masafumi Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akiko Nishitani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tsuyoshi Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Isao Kurosaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shusaku Tsutsui
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Katsuyoshi Hatakeyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Toshirou Nishida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshirou Nishida.

About this article

Cite this article

Hasegawa, J., Kanda, T., Hirota, S. et al. Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy. Int J Clin Oncol 12, 212–217 (2007). https://doi.org/10.1007/s10147-007-0657-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-007-0657-y

Key words

Search

Navigation